Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Polycystic Ovary Syndrome 2Pancreatic Neoplasms 2Melanoma 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Prostate Cancer Recurrent 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Infertility 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Chondrosarcoma 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Breast Diseases 1

Interventions

Doxorubicin 3temsirolimus 1resiquimod 1poly ICLC 1nilotinib 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1envafolimab 1enasidenib 1TQ-B3525 1Sunitinib 1Nivolumab 1Methotrexate 1Metformin 1Ifosfamide 1HhAntag691 1Epirubicin 1Dacarbazine 1Cisplatin 1Chloroquine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Chondrosarcoma × Metformin × Clear all
NCT02496741 2020-01-09

MACIST

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Completed
15 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡